High‐grade serous peritoneal cancer follows a high stromal response signature and shows worse outcome than ovarian cancer
Rattachement africain : ch, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
In the era of personalized medicine, where transition from organ-based to individualized genetic diagnosis takes place, the tailoring of treatment in cancer becomes increasingly important. This is particularly true for high-grade, advanced FIGO stage serous adenocarcinomas of the ovary (OC), fallopian tube (TC), and peritoneum (PC), which are currently all treated identically. We analyzed three independent patient cohorts using histopathologically classified diagnosis and various molecular approaches (transcriptomics, immunohistochemistry, next-generation sequencing, fluorescent and chromogenic in situ hybridization). Using multivariate Cox regression model, we found that PC is more aggressive compared with advanced-stage OC independent of residual disease as shown by an earlier relapse-free survival in two large cohorts (HR: 2.63, CI: 1.59-4.37, P < 0.001, and HR: 1.66, CI: 1.04-2.63, P < 0.033). In line with these findings, transcriptomic data revealed differentially expressed gene signatures identifying PC as high stromal response tumors. The third independent cohort (n = 4054) showed a distinction between these cancer types for markers suggested to be predictive for chemotherapy drug response. Our findings add additional evidence that ovarian and peritoneal cancers are epidemiologically and molecularly distinct diseases. Moreover, our data also suggest consideration of the tumor-sampling site for future diagnosis and treatment decisions.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- High‐grade serous peritoneal cancer follows a high stromal response signature and shows worse outcome than ovarian cancer
- Date Crossref
- 23/10/2020
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Basel pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital of Basel pays non établi dans la noticeÉtablissement de santé
-
Enzo Life Sciences (Switzerland) pays non établi dans la noticeEntreprise
-
Caris Life Sciences (United States) pays non établi dans la noticeEntreprise
-
University Hospital Basel Department of Biomedicine pays non établi dans la noticeUniversité ou école supérieure
-
CARIS Life Sciences International Basel Switzerland pays non établi dans la noticeInstitution
University of Basel, University Hospital of Basel et Enzo Life Sciences (Switzerland), avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.